Analyst consensus rating
Outlook Therapeutics Analyst Rating: none
Direct answer
Outlook Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.03.
Forecast evidence checked October 20, 2026.
Get free Outlook Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.49
- Average price target
- $5.03
- High price target
- $10.50
- Low price target
- $1.60
- Low target gap
- +224.5%
- Target upside
- +919.3%
- High target gap
- +2,029.8%
- Target range width
- 1,805.3%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 20, 2026
- Valid through
- October 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Outlook Therapeutics?
Outlook Therapeutics has a verified none consensus. The same dataset has an average price target of $5.03.
How far are Outlook Therapeutics's low and high targets from the recorded price?
The low target implies +224.5%, while the high target implies +2,029.8%.
How many analysts are included in Outlook Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Outlook Therapeutics's target upside or downside calculated?
The average target of $5.03 is divided by the recorded price of $0.49, then one is subtracted to produce +919.3%. This does not guarantee a future return.
When was Outlook Therapeutics's analyst forecast verified?
The data was verified on 2026-10-20. The dataset is valid through 2026-10-27.